CN Patent

CN105384686B — 一种博舒替尼结晶方法

Assigned to Lianyungang Runzhong Pharmaceutical Co Ltd · Expires 2019-07-26 · 7y expired

What this patent protects

本发明提供了一种博舒替尼结晶方法。本发明将博舒替尼粗品溶于非质子极性溶剂,再加入水,搅拌,降温,析晶,过滤,干燥,制备得博舒替尼结晶。本发明的方法具有升温过程耗能低、无需长时间维持高温转晶、结晶时间短的优点;能够降低生产能耗,减少环境污染,节约生产成本,同时生产周期短,可以提高生产效率。本发明所提供的方法是通过完全溶解博舒替尼,再降温析晶的方法,有利于晶型的彻底转化,且本发明的方法能够降低有关物质含量。

USPTO Abstract

本发明提供了一种博舒替尼结晶方法。本发明将博舒替尼粗品溶于非质子极性溶剂,再加入水,搅拌,降温,析晶,过滤,干燥,制备得博舒替尼结晶。本发明的方法具有升温过程耗能低、无需长时间维持高温转晶、结晶时间短的优点;能够降低生产能耗,减少环境污染,节约生产成本,同时生产周期短,可以提高生产效率。本发明所提供的方法是通过完全溶解博舒替尼,再降温析晶的方法,有利于晶型的彻底转化,且本发明的方法能够降低有关物质含量。

Drugs covered by this patent

Patent Metadata

Patent number
CN105384686B
Jurisdiction
CN
Classification
Expires
2019-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Lianyungang Runzhong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.